Small Cap Voice

Massimo Barone, CEO of SmartCard Marketing, Inc. (OTC: SMKG), a boutique Payments & Incentives technology solutions provider to the global payments industry, called in to discuss the robust year the Company had in 2018 setting the stage for his bullish outlook for 2019. In the interview, Barrone sheds light on the recent news regarding the addition of new capabilities for multiple signatory capture on digital contracts from its Blockchain offering Granularchain.com, its work with partners like Axepay, an update on the global payments industry in 2019 and much more.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. SmallCapVoice.com, Inc. received $750 from the company on 2-4-19 for 30 days of service.

Warren Wang, CEO of ChineseInvestors.com, Inc. (OTC QB: CIIX) ("CIIX" or "the Company"), the premier financial information website for Chinese-speaking investors, called back in to SmallCapVoice.com to go over the driving factors behind the Company's strong financial filing for fiscal Q2. ChineseInvestors.com reported Q2FY2019 Revenues of $648,265, a 43% increase year over year. This increase was driven by stronger subscription revenues and Hemp/CBD sales revenues. Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products. For more information visit ChineseInvestors.com

This interview may include forward looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. CIIX: SmallCapVoice.com, Inc. received $8,000 from a third party on behalf of the issuer on 1-23-17 120 days of service. SmallCapVoice.com, Inc. received $2,500 from a third party on behalf of the issuer on 6-23-17 30 days of service. SmallCapVoice.com, Inc. received $2,500 from a third party on behalf of the issuer on 7-23-17 30 days of service. SmallCapVoice.com, Inc. received $2,500 from a third party on behalf of the issuer on 8-23-17 30 days of service. SmallCapVoice.com, Inc. received $2,500 from a third party on behalf of the issuer on 9-23-17 30 days of service. SmallCapVoice.com, Inc. received $2,500 from a third party on behalf of the issuer on 10-23-17 30 days of service. SmallCapVoice.com, Inc. received $2,500 from a third party on behalf of the issuer on 11-23-17 30 days of service. SmallCapVoice.com, Inc. signed a six month contract for $2,000 per month with a third party on behalf of the issuer on 1-22-18. SmallCapVoice.com, Inc. signed a six month contract for $2,000 per month with a third party on behalf of the issuer on 8-1-18.

Warren Wang, CEO of ChineseInvestors.com, Inc. (OTC QB: CIIX) (“CIIX” or “the Company”), the premier financial information website for Chinese-speaking investors, called back in to SmallCapVoice.com to go over the driving factors behind the Company’s strong financial filing for fiscal Q2. ChineseInvestors.com reported Q2FY2019 Revenues of $648,265, a 43% increase year over year. This increase was driven by stronger subscription revenues and Hemp/CBD sales revenues. Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products. For more information visit ChineseInvestors.com

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. CIIX: SmallCapVoice.com, Inc. received $8,000 from a third party on behalf of the issuer on 1-23-17 120 days of service. SmallCapVoice.com, Inc. received $2,500 from a third party on behalf of the issuer on 6-23-17 30 days of service. SmallCapVoice.com, Inc. received $2,500 from a third party on behalf of the issuer on 7-23-17 30 days of service. SmallCapVoice.com, Inc. received $2,500 from a third party on behalf of the issuer on 8-23-17 30 days of service. SmallCapVoice.com, Inc. received $2,500 from a third party on behalf of the issuer on 9-23-17 30 days of service. SmallCapVoice.com, Inc. received $2,500 from a third party on behalf of the issuer on 10-23-17 30 days of service. SmallCapVoice.com, Inc. received $2,500 from a third party on behalf of the issuer on 11-23-17 30 days of service. SmallCapVoice.com, Inc. signed a six month contract for $2,000 per month with a third party on behalf of the issuer on 1-22-18. SmallCapVoice.com, Inc. signed a six month contract for $2,000 per month with a third party on behalf of the issuer on 8-1-18.

Denis Corin, CEO of Q BioMed Inc. (OTCQB: QBIO), called in to SmallCapvoice.com to go over his company’s business model, the markets they serve, their products and formulations including QBM-001, in support of Q BioMed's Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children, and Metastron.

Q BioMed Inc., 'Q', is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need. Please visit http://www.qbiomed.com and sign up to receive regular updates. Follow us on social media @QBioMed.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

Denis Corin, CEO of Q BioMed Inc. (OTCQB: QBIO), called in to SmallCapvoice.com to go over his company’s business model, the markets they serve, their products and formulations including QBM-001, in support of Q BioMed’s Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children, and Metastron.

Q BioMed Inc., ‘Q’, is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need. Please visit http://www.qbiomed.com and sign up to receive regular updates. Follow us on social media @QBioMed.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

President, CEO, and Director of BioCorRx Inc, (OTCQB: BICX) Brady Granier, called in to SmallCapVoice.com to go over the progress the Company has made in 2018. BioCorRx Inc. is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. SmallCapVoice.com, Inc. received $750 from the company on 12-11-18 for 30 days of service.

President, CEO, and Director of BioCorRx Inc, (OTCQB: BICX) Brady Granier, called in to SmallCapVoice.com to go over the progress the Company has made in 2018. BioCorRx Inc. is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. SmallCapVoice.com, Inc. received $750 from the company on 12-11-18 for 30 days of service.

Nature’s Best Brands, Inc. (OTC: HLTY), soon to be known as PreCheck Health Services, Inc., CEO Lawrence Biggs called in to SmallCapVoice.com to go over his Company’s new business model, markets they operate in, management team and much more.

PreCheck Health Services Inc. (“PHSI” or the “Company”) is a Florida corporation focused on the exclusive U.S. distribution of a medical diagnostic device, the PC8B.

The PC8B medical device is a powerful diagnostic tool in managing patient’s health. Scientifically validated and FDA cleared, this medical device performs a range of tests that are covered and reimbursed by most insurance companies. The manufacturer holds multiple patents on the device and continues to evolve the technology.

This system is non-invasive and combined with a fast ABI (Ankle Brachial Index) test, takes less than 8 minutes to complete an assessment. The device provides physicians with a one-page comprehensive overview of a patient’s health at-a-glance. The screening system provides patient insights covering 8 key risk factors. Depending on the risk score for each factor, the physician will be able to determine the best course of action to resolve the patient’s condition, as well as motivate the patient to immediate action.

The Company’s headquarters are located in Denison Texas.

The Company’s CEO, Mr. Lawrence Biggs has previous public company experience. He was the Chairman and Chief Executive Officer of Max Internet Communications, Inc., (NASDAQ:MXIP), which was focused on sales and distribution of specialty computer hardware that enabled high-resolution video conferencing. At its peak, the company reached a market cap of over $1.2 billion dollars.

The operating team has extensive experience in marketing, processing, billing and screening of the PC8B device, as well as having the deep medical knowledge regarding early detection of disease.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

Nature’s Best Brands, Inc. (OTC: HLTY), soon to be known as PreCheck Health Services, Inc., CEO Lawrence Biggs called in to SmallCapVoice.com to go over his Company’s new business model, markets they operate in, management team and much more.

PreCheck Health Services Inc. (“PHSI” or the “Company”) is a Florida corporation focused on the exclusive U.S. distribution of a medical diagnostic device, the PC8B.

The PC8B medical device is a powerful diagnostic tool in managing patient’s health. Scientifically validated and FDA cleared, this medical device performs a range of tests that are covered and reimbursed by most insurance companies. The manufacturer holds multiple patents on the device and continues to evolve the technology.

This system is non-invasive and combined with a fast ABI (Ankle Brachial Index) test, takes less than 8 minutes to complete an assessment. The device provides physicians with a one-page comprehensive overview of a patient’s health at-a-glance. The screening system provides patient insights covering 8 key risk factors. Depending on the risk score for each factor, the physician will be able to determine the best course of action to resolve the patient’s condition, as well as motivate the patient to immediate action.

The Company’s headquarters are located in Denison Texas.

The Company’s CEO, Mr. Lawrence Biggs has previous public company experience. He was the Chairman and Chief Executive Officer of Max Internet Communications, Inc., (NASDAQ:MXIP), which was focused on sales and distribution of specialty computer hardware that enabled high-resolution video conferencing. At its peak, the company reached a market cap of over $1.2 billion dollars.

The operating team has extensive experience in marketing, processing, billing and screening of the PC8B device, as well as having the deep medical knowledge regarding early detection of disease.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

Nature’s Best Brands, Inc. (OTC: HLTY), soon to be known as PreCheck Health Services, Inc., CEO Lawrence Biggs called in to SmallCapVoice.com to go over his Company’s new business model, markets they operate in, management team and much more.

PreCheck Health Services Inc. (“PHSI” or the “Company”) is a Florida corporation focused on the exclusive U.S. distribution of a medical diagnostic device, the PC8B.

The PC8B medical device is a powerful diagnostic tool in managing patient’s health. Scientifically validated and FDA cleared, this medical device performs a range of tests that are covered and reimbursed by most insurance companies. The manufacturer holds multiple patents on the device and continues to evolve the technology.

This system is non-invasive and combined with a fast ABI (Ankle Brachial Index) test, takes less than 8 minutes to complete an assessment. The device provides physicians with a one-page comprehensive overview of a patient’s health at-a-glance. The screening system provides patient insights covering 8 key risk factors. Depending on the risk score for each factor, the physician will be able to determine the best course of action to resolve the patient’s condition, as well as motivate the patient to immediate action.

The Company’s headquarters are located in Denison Texas.

The Company’s CEO, Mr. Lawrence Biggs has previous public company experience. He was the Chairman and Chief Executive Officer of Max Internet Communications, Inc., (NASDAQ:MXIP), which was focused on sales and distribution of specialty computer hardware that enabled high-resolution video conferencing. At its peak, the company reached a market cap of over $1.2 billion dollars.

The operating team has extensive experience in marketing, processing, billing and screening of the PC8B device, as well as having the deep medical knowledge regarding early detection of disease.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.